Based on this study, cabozantinib (CabometyxTM, Exelixis and Ipsen, Inc.)was approved in April 2016 by the FDA and in July 2016 by the EMA for the treatment of advanced RCC in patients who have received prior anti-VEGF target therapy. This evidence concerns the gene VEGFA and renal cell carcinoma.